Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 13/07/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 13/07/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 15/06/2017

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 15/06/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Trizivir, abacavir (as sulfate) / lamivudine / zidovudine, HIV Infections, Date of authorisation: 27/12/2000, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Trizivir, abacavir (as sulfate) / lamivudine / zidovudine, HIV Infections, Date of authorisation: 27/12/2000, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Sleep Initiation and Maintenance Disorders;Autistic Disorder, Date of authorisation: 20/09/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Sleep Initiation and Maintenance Disorders;Autistic Disorder, Date of authorisation: 20/09/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis, Date of authorisation: 17/02/2017, Revision:

Human medicines European public assessment report (EPAR): Truxima, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis, Date of authorisation: 17/02/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 01/04/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid;Microscopic Polyangiitis;Pemphigus, Date of authorisation: 01/04/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Advate, octocog alfa, Hemophilia A, Date of authorisation: 02/03/2004, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Advate, octocog alfa, Hemophilia A, Date of authorisation: 02/03/2004, Revision: 32, Status: Authorised

Beta-alanine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/10510/202301

Beta-alanine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/10510/202301

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness